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The immune system is the built-in host defense mechanism against infectious agents as well as cancer.
Protective immunity against cancer was convincingly demonstrated in the 1940s with syngeneic animal models
(JNCI 18:769-778, 1976; Cancer Immun 1:6, 2001). Since then, the last century’s dream has been to effectively
prevent and cure cancers by immunological means. This dream has slowly but surely become a reality (Nature
480:480-489, 2011). The successful examples of immunoprophylaxis and therapy against cancers include: (i) targeted
therapy using monoclonal antibodies (Nat Rev Cancer 12:278-287, 2012); (ii) allogeneic hematopoietic stem cell
transplantion to elicit graft-versus-cancer effect against a variety of hematopoietic malignancies (Blood 112:4371-
4383, 2008); (iii) vaccination for preventing cancers with clear viral etiology such as hepatocellular carcinoma and
cervical cancer (Cancer J Clin 57:7-28, 2007; NEJM 336:1855-1859, 1997); (iv) T cell checkpoint blockade against
inhibitory pathways including targeting CTLA-4 and PD-1 inhibitory molecules for the treatment of melanoma
and other solid tumors (NEJM 363:711-723, 2010; NEJM 366:2443-2454, 2012; NEJM 369:122-133, 2013; NEJM
366:2455-2465, 2012); (v) antigen-pulsed autologous dendritic cell vaccination against prostate cancer (NEJM
363:411-422, 2010); and (vi) the transfer of T cells including those genetically engineered with chimeric antigen
receptors allowing targeting of B cell neoplasms (NEJM 365:725-733, 2011; NEJM 368:1509-1518, 2013; Blood
118:4817-4828, 2013; Sci Transl Med 5:177ra138, 2013).
This article provides an overview on the exciting and expanding immunological arsenals against cancer, and
discusses critical remaining unanswered questions of cancer immunology. The inherent specificity and memory of
the adaptive immune response towards cancer will undoubtedly propel cancer immunotherapy to the forefront of
cancer treatment in the immediate near future. Study of the fundamental mechanisms of the immune evasion of
cancer shall also advance the field of immunology towards the development of effective immunotherapeutics
against a wide spectrum of human diseases.Introduction
Cancer immunotherapy has come a long way [1-16]. In
the late 1800 s, William Coley was one of a growing
number of investigators who noticed a correlation be-
tween regression of cancer and infection [17-20]. Coley
expanded on this observation and became the first per-
son to treat substantial numbers of cancer patients with
a mixture of killed bacteria (known as Coley’s toxin).
Although not meeting the standards of today’s trials,
Coley achieved tumor regression in a relatively high pro-
portion of sarcoma patients. Despite much enthusiasm,
the advent of immune-suppressing radiation therapy and
chemotherapy which could directly impact cancer pro-
gression diverted much attention away from immune-* Correspondence: zihai@musc.edu
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stated.based therapies [17,18]. Furthermore, as the immune
system was not well understood, there was much
skepticism that tumor cells could be different from self
and capable of eliciting immune-mediated eradiation.
However, with growing understanding of how the im-
mune system functioned, in 1957, Frank Macfarlane
Burnet proposed a revolutionary concept that cancer
cells may have antigenic differences allowing immune-
mediated eradication [21]. This seed of great expectation
raised hope that one day cancers might be routinely and
effectively treated by immunological means. While there
has been much optimism over the past 50 years, it is
only during the last decade that this optimism has been
met with true meaningful progress [22,23]. There is now
no question that cancer immunology has entered into a
period of renaissance [24,25], thanks largely to the af-
firmative and emphatic answer to several fundamental
questions: (i) does cancer immunity exist? [2] (ii) canhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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established cancer? [16,26] (iii) does host immune
defense exert pressure to cancer during oncogenesis?
[27,28] (iv) are there tumor-specific and/or tumor-
associated antigens? [29-31] (v) can immune tolerance
to cancer be broken to result in therapeutic benefit?
[8,10,32] Therefore, it is not a question of “if” but for
many cancers “when” immunotherapy will be the main
treatment modality.
Established practice of immunotherapy of cancer
Cancer immunotherapy has already entered the main-
stream of oncology [23]. Existing strategies focus on en-
hancing immune destruction of cancer cells by a variety
of means (Table 1). One of the most successful and
longstanding forms of cell-based immunotherapy is
allogeneic stem cell transplant for the treatment of
hematological malignancies. Although stem cell trans-
plantation was initially thought to enhance cancer cure
by allowing myeloablative therapy in the forms of high
dose chemotherapy and total body irradiation [33], it has
become clear that allogeneic immune response against
tumor cells is a key mechanism of action [5]. The
antibody-based strategy against cancer continues to
make impact in cancer care, as antibodies can eliminate
cancer cells via immunological means (through antibody
or complement-dependent cytotoxicty) as well as via
other biological means (e.g., blocking key oncogenic
signals) [22,34,35]. In addition, immunomodulating cyto-
kines remain important in the treatment of selected
tumor types, such as the use of type I interferon as an
adjuvant therapy for high-risk melanoma [36]. One
significant milestone in the field of cancer immunology
was the 2010 FDA-approval of sipuleucel-T (Sip-T), an
autologous dendritic cell preparation, loaded with recom-
binant fusion protein between GM-CSF and prostate-
specific acid phosphatase, for the treatment of metastatic
prostate cancer [12]. Sip-T represents the first of its kind
of therapeutic vaccine against cancer using dendritic cell-
based platform [37]. In 2011, the FDA approved ipilimu-
mab injection for the treatment of unresectable orTable 1 Examples of FDA-approved cancer immunotherapeut
Modality
Hematopoietic stem cell transplantion (e.g., leukemia and myeloma)
Antibody (e.g., retuximab, trastuzumab)
Cytokines (e.g., type I interferon, interleukin-2)
Dendritic cells (e.g., Sip-T for prostate cancer)
T cell checkpoint blockade (e.g., Ipilumimab for melanoma)
Microbes (e.g., BCG for the transitional bladder cancer)metastatic melanoma. Ipilimumab represents a new class
of cancer immunotherapeutics based on blockage of nega-
tive T cell check-point signal [3,38]. Tumor-specific T cells
can be activated by professional antigen presenting cells
through engagement of T cell receptor and co-stimulatory
molecules such as CD28. However, to maintain immune
homeostasis, activated T cells have to be temporally
turned off via engaging inhibitory receptors on T cells
such as CTLA-4 [39,40]. Ipilimumab is a fully human
monoclonal antibody that binds and blocks CTLA-4 to
sustain T cell activity, and it has been shown to improve
overall survival of patients with advanced melanoma [8].
Importantly, maximizing T cell co-stimulation was
demonstrated to be an effective anti-tumor strategy as
early as 1992 when stable expression of the B7 molecule
in tumor cells was shown to result in T-cell specific tumor
eradication [41].
What is hot in cancer immunotherapy in 2013?
Three kinds of cancer immunotherapeutics have emerged
as key breakthroughs in clinical cancer care in 2013. These
advances include T cell checkpoint blockers (Figure 1A),
adoptive therapy with T cells genetically modified with
chimeric antigen receptor (CAR) (Figure 1B), and targeted
monoclonal antibody therapy (Figure 1C).
Recent findings demonstrate that a variety of functionally
non-overlapping co-inhibitory receptors can be expressed
by T cells to turn off their effector function [3,42]. These in-
hibitory receptors include CTLA-4, PD-1, TIM-3, BTLA,
PD-1H (VISTA) and LAG-3. While in theory, blocking any
of these inhibitory receptors could lead to increased activa-
tion of tumor-reactive T cells, systemic activation of T cells
does not necessarily lead to more effective anti-tumor activ-
ity. Blockade of CTLA-4 with antibody led to tumor regres-
sion in 10-15% patients with advanced melanoma whereas
severe autoimmune toxicity was evident in >30% of pa-
tients. Therefore, a strategy to selectively manipulate tumor
microenvironment rather than systemic promotion of T cell
immunity is desirable. It is particularly promising as many
tumor cells express ligands for the co-inhibitory receptors,
such as PD-L1 (also known as B7-H1), the ligand for PD-1ic agents
Principle
1. Reset the immune system
2. Allo-antigen response (graft versus tumor effect)
1. Eliminate cancer cells
2. Block key signaling pathways
Boost both innate and adaptive immunity
Enhance tumor-specific T cell priming
Block/reverse immune tolerance
Enhance innate and adaptive immunity
Figure 1 Emerging effective immunotherapies of cancer. A. T
cell checkpoint blocker. B. Adoptive therapy with CAR-enforced T
cells. C. Monoclonal antibody therapy.
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normal tissues [43]. Indeed, 9 of 25 patients (36%) with PD-
L1-positive advanced tumors had an objective response to
anti-PD-1 antibody therapy [9]. Surprisingly, when nivolu-
mab (anti-PD-1 antibody) and ipilimumab were given to
patients with advanced melanoma concurrently every
3 weeks for 4 doses, followed by nivolumab alone every
3 weeks for 4 doses, 53% of patients had an objective re-
sponse, all with tumor reduction of 80% or more [10].
This study demonstrated the potential to combine mul-
tiple T cell checkpoint blockade to maximize anti-cancer
immunity, with acceptable toxicity. Because this type of
immunotherapy depends on a healthy immune system,
conventional cancer treatments including chemotherapy
and radiation therapy often impair immune system and
could decrease the efficacy of this therapy. The field iswaiting with anticipation of data of frontline therapy with
T cell checkpoint blockade of cancer patients.
Several proof-of-principle studies have demonstrated
the huge potential of utilizing synthetic immunology to
engineer CAR-expressing or TCR-expressing T cells for
the adoptive therapy of select cancers including lympho-
cytic leukemia [44-46]. Building off work from Steven
Rosenberg’s group [47], Carl June and his colleagues
successfully engineered a CD19-reactive CAR composed
of a fusion protein between extracellular single chain
anti-CD19 antibody, the transmembrane domain, 4-1BB
(CD137) survival signal, and the CD3ς chain signaling
motif [48]. Autologous T cells transduced with the
CD19-reactive CAR were shown to have potent clinical
activity against CD19+ tumors after infusion in three of
three patients with advanced chronic lymphocytic
leukemia (CLL) [13]. In April 2013, it was reported that
two children with relapsed and refractory pre-B-cell
acute lymphocytic leukemia received infusions of T cells
transduced with CD19-reactive CAR [14]. In both
patients, these T cells expanded to a level that was more
than 1000 times as high as the initial engraftment level,
and the cells were identified in bone marrow. In
addition, the CAR+ T cells were observed in the cerebro-
spinal fluid. More importantly, complete remission was
observed in both patients and is ongoing in one patient
at 11 months after treatment at the time of the report.
The other patient had a relapse, with blast cells that no
longer expressed CD19, approximately 2 months after
treatment. Thus, CAR-modified T cells are capable of
killing even aggressive, treatment-refractory acute
leukemia cells in vivo. Indeed, Michel Sadelain’s group
treated five relapsed acute B cell lymphocytic leukemia
subjects with autologous T cells expressing a CD19-
reactive CD28/CD3ζ second-generation dual-signaling
CAR [16]. All patients with persistent disease upon T
cell infusion demonstrated rapid tumor eradication and
achieved complete molecular remissions as assessed by
polymerase chain reaction, therefore, this therapy
appears to be very promising in treating hematopoietic
malignancies. It will be interesting to see whether the
same approach could also be applied successfully for the
treatment of solid tumors.
2013 continues to witness the increasing application of
monoclonal antibody for cancer immunotherapy [22].
Approved monoclonal antibodies by the FDA in 2013
include Ado-trastuzumab emtansine and pertuzumab for
Her2+ breast cancer, denosumab for giant cell tumor of
the bone, bevacizumab for both first and second line
therapy for metastatic colorectal cancer in combination
with chemotherapy. Ever since anti-CD3 antibody was
approved in 1986 for the treatment of autoimmune dis-
eases, more than 35 antibodies have been introduced to
the market with a significant portion of them indicated
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body), Herceptin (anti-Her2 antibody), and Ipilimumab
(anti-CTLA-4 antibody).
Key unanswered questions in cancer immunology
The current enthusiasm in cancer immunology raises
the question of whether all cancers may be amenable by
immune intervention. As a basis for addressing this
question and making existing therapies more effective,
there are four critical unanswered questions (Table 2).
First, what is the molecular entity in cancer that triggers
the initial immune response particularly during advan-
ced disease? If we understand the antigens the immune
system targets successfully in cancers known to be im-
mune amenable, we may be able to better identify such
antigens in patients with other types of cancer. Second,
what determines the outcome of tumor immunity? We
need to be mindful that tumors are not bacteria, virus or
parasites. The quality of immune response to cancer
cannot simply be viewed through the conventional
immunological prisms we use to predict the immune
response against infectious agents. Third, what is the
mechanism of tumor evasion? In this case, the answer
might have to come from the study of the tumor micro-
environment rather than systemic suppression. Finally,
as much as we all hope to have a universal cancer
vaccine on a population basis [49], immunotherapy of
established (clinically detectable) cancer may often need
to be individualized. Figuring out how to combine vari-
ous arsenals in the immune system in a tailored fashion
to individual patients is a challenge as well as a wonder-
ful opportunity for future research.
Goals of cancer immunotherapy and perspective: are we
there yet?
Slowly but surely there has been a growing paradigm
shift in the understanding of biology and immun-
ology of cancer. This is evident from the essay by
Douglas Hanahan and Robert Weinberg on the Hall-
marks of Cancer (The Next Generation) in 2011Table 2 A few key research themes in cancer immunology
Theme Research question
Immune recognition of cancer What are characteristics of an
Do these antigens exist for al
Fate determination of tumor immunity Tumors are not bacteria, not
and innate immunity signals
Mechanism of immune evasion Are immune evasion and onc
oncoinflammation in the tum
Immunotherapy It is time to redefine the goa
immunogenic ones. What is t
chemotherapy or targeted th
including novel targets (e.g.,
novel adjuvants, novel cytoki
status to immunogenic one.which added “avoiding immune destruction” and
“tumor-promoting inflammation” as another two
hallmarks of cancer to their original perspective [50].
Given that the immune system has a remarkable
ability to detect, “remember” and eliminate cancer
cells, it is becoming clear that immunotherapy is not
simply a means of cancer treatment. Rather, estab-
lishing long-lasting, cancer-specific immunity can be
a goal to allow for curative therapy. In addition, de-
velopment of effective immunotherapeutic cancer
strategies requires our attention to deal with both of
the immunological hallmarks of cancer: “avoiding
immune destruction” and “tumor-promoting inflam-
mation”. Presently, most of the approved cancer im-
munotherapeutics (Table 1) focus on maximizing
immune destruction of cancers. No specific modal-
ities are available clinically to silence “tumor-pro-
moting inflammation”, other than antibiotics and
vaccines to eliminate microbes-associated cancer. We
are just starting to understand how cancer cells
“avoiding immune destruction”. Defining and blunt-
ing oncoinflammation will likely prove critical in the
future for achieving effective anti-cancer immune re-
sponses (Table 2).
Immunotherapy of cancer is no longer a dream. Gone
is the time when elimination of cancer by immunological
means was anecdotal or achievable only in animal stud-
ies. Immune-based therapies have now demonstrated
efficacy in a range of clinical studies and types of cancer.
Adoptive transfer of tumor-reactive T cells can cure
select patients with advanced metastatic disease that
have exhausted all other options. Other reagents, such
as selective manipulation of T cell checkpoint blockers
in cancer microenvironment, offer the possibility of off-
the-shelf dosing or novel combinatorial therapies. More
than ever before, the field of cancer immunology is per-
meated with a sense of optimism [23]. The key question
today is not whether immune-based therapies will trans-
form cancer therapy, but how will these approaches
transform cancer medicine in the future.tigens critical for immune recognition of cancer cells?
l cancers?
viruses, and not parasites. How do differences in antigen presentation
impact the ability to initiate and mediate effective anti-tumor immunity?
ogenesis closely coupled? What is the molecular definition of
or environment and its impact on cancer immunity?
ls of conventional therapy to convert non-immunogenic signals to
he best strategy to combine immunotherapy with radiation therapy,
erapy? More innovative immunotherapeutic strategies are needed
cancer stem cells), novel sources of antigens (subdominant antigens),
nes and new ways to reset the immune system from tolerogenic
Li et al. Experimental Hematology & Oncology 2013, 2:33 Page 5 of 6
http://www.ehoonline.org/content/2/1/33Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All authors wrote, reviewed and approved the manuscript.
Acknowledgements
This article was presented in part recently in a lecture (by Z.L) given to the
2013 Joint Conference on Immunotherapy of Cancer by the Society of
Immunotherapy of Cancer (SITC), Chinese America Hematologist and
Oncologist Network (CAHON), and the Chinese Society of Clinical Oncology
(CSCO) in Xiamen, China.
Author details
1Hollings Cancer Center, Medical University of South Carolina, Charleston, SC
29425, USA. 2Yale Cancer Center, Yale University School of Medicine, New
Haven, CT 06514, USA.
Received: 8 November 2013 Accepted: 4 December 2013
Published: 10 December 2013
References
1. Prehn RT, Main JM: Immunity to methylcholanthrene-induced sarcomas.
J Natl Cancer Inst 1957, 18:769–778.
2. Klein G: The strange road to the tumor-specific transplantation antigens
(TSTAs). Cancer Immun 2001, 1:6.
3. Mellman I, Coukos G, Dranoff G: Cancer immunotherapy comes of age.
Nature 2011, 480(7378):480–489.
4. Scott AM, Wolchok JD, Old LJ: Antibody therapy of cancer. Nat Rev Cancer
2012, 12(4):278–287.
5. Kolb HJ: Graft-versus-leukemia effects of transplantation and donor
lymphocytes. Blood 2008, 112(12):4371–4383.
6. Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG, Goldie SJ,
Harper DM, Kinney W, Moscicki AB, et al: American cancer society
guideline for human papillomavirus (HPV) vaccine use to prevent
cervical cancer and its precursors. CA Cancer J Clin 2007, 57(1):7–28.
7. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY,
Chen DS: Universal hepatitis B vaccination in Taiwan and the incidence
of hepatocellular carcinoma in children: Taiwan childhood hepatoma
study group. N Engl J Med 1997, 336(26):1855–1859.
8. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB,
Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al: Improved survival
with ipilimumab in patients with metastatic melanoma. N Engl J Med
2010, 363(8):711–723.
9. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF,
Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al: Safety, activity, and
immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012,
366(26):2443–2454.
10. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM,
Segal NH, Ariyan CE, Gordon RA, Reed K, et al: Nivolumab plus ipilimumab
in advanced melanoma. N Engl J Med 2013, 369(2):122–133.
11. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG,
Camacho LH, Kauh J, Odunsi K, et al: Safety and activity of anti-PD-L1
antibody in patients with advanced cancer. N Engl J Med 2012,
366(26):2455–2465.
12. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern
CH, Ferrari AC, Dreicer R, Sims RB, et al: Sipuleucel-T immunotherapy for
castration-resistant prostate cancer. N Engl J Med 2010, 363(5):411–422.
13. Porter DL, Levine BL, Kalos M, Bagg A, June CH: Chimeric antigen
receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med
2011, 365(8):725–733.
14. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR,
Teachey DT, Chew A, Hauck B, Wright JF, et al: Chimeric antigen
receptor-modified T cells for acute lymphoid leukemia. N Engl J Med
2013, 368(16):1509–1518.
15. Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C,
Yeh R, Bartido S, Borquez-Ojeda O, et al: Safety and persistence of
adoptively transferred autologous CD19-targeted T cells in patients with
relapsed or chemotherapy refractory B-cell leukemias. Blood 2013,
118(18):4817–4828.16. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S,
Stefanski J, Taylor C, Olszewska M, et al: CD19-targeted T cells rapidly
induce molecular remissions in adults with chemotherapy-refractory
acute lymphoblastic leukemia. Sci Transl Med 2013, 5(177):177ra138.
17. McCarthy EF: The toxins of William B Coley and the treatment of bone
and soft-tissue sarcomas. Iowa Orthop J 2006, 26:154–158.
18. Hoption Cann SA, Van Netten JP, Van Netten C, Glover DW: Spontaneous
regression: a hidden treasure buried in time. Med Hypotheses 2002,
58(2):115–119.
19. Hobohm U: Fever and cancer in perspective. Cancer Immunol Immunother
2001, 50(8):391–396.
20. Goldstein MG, Li Z: Heat-shock proteins in infection-mediated
inflammation-induced tumorigenesis. J Hematol Oncol 2009, 2:5.
21. Burnet M: Cancer; a biological approach: I: the processes of control.
Br Med J 1957, 1(5022):779–786.
22. Sliwkowski MX, Mellman I: Antibody therapeutics in cancer. Science 2013,
341(6151):1192–1198.
23. DeVita VT Jr, Rosenberg SA: Two hundred years of cancer research. N Engl
J Med 2012, 366(23):2207–2214.
24. Sawyers CL, Abate-Shen C, Anderson KC, Barker A, Baselga J, Berger NA,
Foti M, Jemal A, Lawrence TS, Li CI, et al: Cancer progress report 2013.
Clin Cancer Res 2013, 19(20 Suppl):S4–98.
25. Eggermont AM, Kroemer G, Zitvogel L: Immunotherapy and the concept
of a clinical cure. Eur J Cancer 2013, 49(14):2965–2967.
26. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM,
Royal RE, Topalian SL, Kammula US, Restifo NP, et al: Cancer regression in
patients after transfer of genetically engineered lymphocytes.
Science 2006, 314(5796):126–129.
27. Smyth MJ, Godfrey DI, Trapani JA: A fresh look at tumor
immunosurveillance and immunotherapy. Nat Immunol 2001,
2(4):293–299.
28. Schreiber RD, Old LJ, Smyth MJ: Cancer immunoediting: integrating
immunity’s roles in cancer suppression and promotion. Science 2011,
331(6024):1565–1570.
29. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P: Human T cell
responses against melanoma. Annu Rev Immunol 2006, 24:175–208.
30. Vigneron N, Stroobant V, Van den Eynde BJ, van der Bruggen P: Database
of T cell-defined human tumor antigens: the 2013 update. Cancer Immun
2013, 13:15.
31. Liu B, Nash J, Runowicz C, Swede H, Stevens R, Li Z: Ovarian cancer
immunotherapy: opportunities, progresses and challenges. J Hematol
Oncol 2010, 3:7.
32. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, De Jong LA,
Vyth-Dreese FA, Dellemijn TA, Antony PA, Spiess PJ, Palmer DC, et al: Tumor
regression and autoimmunity after reversal of a functionally tolerant
state of self-reactive CD8+ T cells. J Exp Med 2003, 198(4):569–580.
33. Thomas ED: Bone marrow transplantation: a review. Semin Hematol 1999,
36(4 Suppl 7):95–103.
34. Ferris RL, Jaffee EM, Ferrone S: Tumor antigen-targeted, monoclonal
antibody-based immunotherapy: clinical response, cellular immunity,
and immunoescape. J Clin Oncol 2010, 28(28):4390–4399.
35. Pandey JP, Li Z: The forgotten tale of immunoglobulin allotypes in cancer
risk and treatment. Exp Hematol Oncol 2013, 2(1):6.
36. Agarwala SS: An update on pegylated IFN-alpha2b for the adjuvant
treatment of melanoma. Expert Rev Anticancer Ther 2012, 12(11):1449–1459.
37. Steinman RM, Mellman I: Immunotherapy: bewitched, bothered, and
bewildered no more. Science 2004, 305(5681):197–200.
38. Zou W, Chen L: Inhibitory B7-family molecules in the tumour
microenvironment. Nat Rev Immunol 2008, 8(6):467–477.
39. Krummel MF, Allison JP: CD28 and CTLA-4 have opposing effects on the
response of T cells to stimulation. J Exp Med 1995, 182(2):459–465.
40. Leach DR, Krummel MF, Allison JP: Enhancement of antitumor immunity
by CTLA-4 blockade. Science 1996, 271(5256):1734–1736.
41. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA,
McGowan P, Linsley PS: Costimulation of antitumor immunity by the B7
counterreceptor for the T lymphocyte molecules CD28 and CTLA-4.
Cell 1992, 71(7):1093–1102.
42. Pardoll DM: The blockade of immune checkpoints in cancer
immunotherapy. Nat Rev Cancer 2012, 12(4):252–264.
43. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC,
Lu J, Zhu G, Tamada K, et al: Tumor-associated B7-H1 promotes T-cell
Li et al. Experimental Hematology & Oncology 2013, 2:33 Page 6 of 6
http://www.ehoonline.org/content/2/1/33apoptosis: a potential mechanism of immune evasion. Nat Med 2002,
8(8):793–800.
44. Restifo NP, Dudley ME, Rosenberg SA: Adoptive immunotherapy for
cancer: harnessing the T cell response. Nat Rev Immunol 2012,
12(4):269–281.
45. Riddell SR, Jensen MC, June CH: Chimeric antigen receptor–modified T
cells: clinical translation in stem cell transplantation and beyond.
Biol Blood Marrow Transplant 2013, 19(1 Suppl):S2–S5.
46. Kershaw MH, Westwood JA, Darcy PK: Gene-engineered T cells for cancer
therapy. Nat Rev Cancer 2013, 13(8):525–541.
47. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M,
Feldman SA, Maric I, Raffeld M, Nathan DA, Lanier BJ, et al: Eradication of
B-lineage cells and regression of lymphoma in a patient treated with
autologous T cells genetically engineered to recognize CD19. Blood 2010,
116(20):4099–4102.
48. Kalos M, June CH: Adoptive T cell transfer for cancer immunotherapy in
the era of synthetic biology. Immunity 2013, 39(1):49–60.
49. Li Y, Zeng H, Xu RH, Liu B, Li Z: Vaccination with human pluripotent stem
cells generates a broad spectrum of immunological and clinical
responses against colon cancer. Stem Cells 2009, 27(12):3103–3111.
50. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation.
Cell 2011, 144(5):646–674.
doi:10.1186/2162-3619-2-33
Cite this article as: Li et al.: Cancer immunotherapy: are we there yet?
Experimental Hematology & Oncology 2013 2:33.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
